IPG Photonics has entered into a binding offer to acquire Lumibird Medical for €300 million on a cash-free, debt-free basis, with up to €50 million in additional contingent earnout consideration based on 2026 and 2027 performance metrics. The acquisition, which will be funded with cash on hand, is expected to close in the fourth quarter of 2026 and be accretive to gross margin, EBITDA, and adjusted EPS. Lumibird Medical, a global leader in ophthalmic diagnostic and treatment systems, reported revenue of €112.2 million and EBITDA of €24.1 million for the fiscal year ended December 31, 2025, representing an EBITDA margin of 21.5%. IPG believes the combined medical businesses will create a scaled platform for growth, adding approximately $1 billion in addressable market for its Advanced Solutions portfolio.
IPG Photonics CorporationIPG makes binding offer to acquire Lumibird Medical for €300M, funded with cash, expected to be accretive to margins and EPS.